Literature DB >> 25267665

Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.

Hyeun Bum Kim1, Quanshun Zhang2, Xingmin Sun2, Gillian Beamer2, Yuankai Wang2, Saul Tzipori3.   

Abstract

The efficacy of oral tigecycline treatment (2 mg/kg of body weight for 7 days) of Clostridium difficile infection (CDI) was evaluated in the gnotobiotic pig model, and its effect on human gut microflora transplanted into the gnotobiotic pig was determined. Tigecycline oral treatment improved survival, clinical signs, and lesion severity and markedly decreased concentrations of Firmicutes but did not promote CDI. Our data showed that oral tigecycline treatment has a potential beneficial effect on the treatment of CDI.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25267665      PMCID: PMC4249528          DOI: 10.1128/AAC.03447-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.

Authors:  Bjorn L Herpers; Bart Vlaminckx; Olaf Burkhardt; Harmjo Blom; Hazra S Biemond-Moeniralam; Mathias Hornef; Tobias Welte; Edward J Kuijper
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

2.  The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice.

Authors:  Peter J Turnbaugh; Vanessa K Ridaura; Jeremiah J Faith; Federico E Rey; Rob Knight; Jeffrey I Gordon
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

3.  Longitudinal investigation of the age-related bacterial diversity in the feces of commercial pigs.

Authors:  Hyeun Bum Kim; Klaudyna Borewicz; Bryan A White; Randall S Singer; Srinand Sreevatsan; Zheng Jin Tu; Richard E Isaacson
Journal:  Vet Microbiol       Date:  2011-05-19       Impact factor: 3.293

4.  A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Authors:  Haiying Wang; Xingmin Sun; Yongrong Zhang; Shan Li; Kevin Chen; Lianfa Shi; Weijia Nie; Raj Kumar; Saul Tzipori; Jufang Wang; Tor Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

Review 5.  Clostridium difficile infection: a comprehensive review.

Authors:  Melina Kachrimanidou; Nikolaos Malisiovas
Journal:  Crit Rev Microbiol       Date:  2011-05-24       Impact factor: 7.624

6.  Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.

Authors:  Robin L P Jump; Yuejin Li; Michael J Pultz; Georgios Kypriotakis; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 7.  Treating Clostridium difficile infection with fecal microbiota transplantation.

Authors:  Johan S Bakken; Thomas Borody; Lawrence J Brandt; Joel V Brill; Daniel C Demarco; Marc Alaric Franzos; Colleen Kelly; Alexander Khoruts; Thomas Louie; Lawrence P Martinelli; Thomas A Moore; George Russell; Christina Surawicz
Journal:  Clin Gastroenterol Hepatol       Date:  2011-08-24       Impact factor: 11.382

8.  Piglet models of acute or chronic Clostridium difficile illness.

Authors:  Jennifer Steele; Hanping Feng; Nicola Parry; Saul Tzipori
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

9.  QIIME allows analysis of high-throughput community sequencing data.

Authors:  J Gregory Caporaso; Justin Kuczynski; Jesse Stombaugh; Kyle Bittinger; Frederic D Bushman; Elizabeth K Costello; Noah Fierer; Antonio Gonzalez Peña; Julia K Goodrich; Jeffrey I Gordon; Gavin A Huttley; Scott T Kelley; Dan Knights; Jeremy E Koenig; Ruth E Ley; Catherine A Lozupone; Daniel McDonald; Brian D Muegge; Meg Pirrung; Jens Reeder; Joel R Sevinsky; Peter J Turnbaugh; William A Walters; Jeremy Widmann; Tanya Yatsunenko; Jesse Zaneveld; Rob Knight
Journal:  Nat Methods       Date:  2010-04-11       Impact factor: 28.547

10.  The Ribosomal Database Project: improved alignments and new tools for rRNA analysis.

Authors:  J R Cole; Q Wang; E Cardenas; J Fish; B Chai; R J Farris; A S Kulam-Syed-Mohideen; D M McGarrell; T Marsh; G M Garrity; J M Tiedje
Journal:  Nucleic Acids Res       Date:  2008-11-12       Impact factor: 16.971

View more
  6 in total

1.  Evaluation of growth and sporulation of a non-toxigenic strain of Clostridioides difficile (Z31) and its shelf viability.

Authors:  Carlos Augusto Oliveira Júnior; Rodrigo Otávio Silveira Silva; Diogo Soares Gonçalves Cruz; Isadora Honorato Pires; Guilherme Guerra Alves; Francisco Carlos Faria Lobato
Journal:  Braz J Microbiol       Date:  2018-12-18       Impact factor: 2.476

2.  An in vitro combined antibiotic-antibody treatment eliminates toxicity from Shiga toxin-producing Escherichia coli.

Authors:  Craig Skinner; Guodong Zhang; Stephanie Patfield; Xiaohua He
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

3.  Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.

Authors:  Emma C Phillips; Cirle A Warren; Jennie Z Ma; Gregory R Madden
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

4.  A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During Clostridium difficile Infection in Association with a Gastrointestinal Microbial Shift.

Authors:  Hyeun Bum Kim; Yuankai Wang; Xingmin Sun
Journal:  J Microbiol Biotechnol       Date:  2016-03       Impact factor: 2.351

5.  Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, Nonoperative Clostridium difficile Infection?

Authors:  Mary T LaSalvia; Westyn Branch-Elliman; Graham M Snyder; Monica V Mahoney; Carolyn D Alonso; Howard S Gold; Sharon B Wright
Journal:  Open Forum Infect Dis       Date:  2017-02-10       Impact factor: 3.835

Review 6.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.